Panipenem-betamipron and decreases in serum valproic acid concentration

Therapeutic Drug Monitoring

Volumn 20, Issue 4, 1998, Pages 396-400

  Yamagata, Takanori ^a   Momoi, Mariko Y ^a   Murai, Kaori ^a   Ikematsu, Kaori ^a   Suwa, Kiyotaka ^a   Sakamoto, Kouichi ^a   Fujimura, Akio ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Carbapenem; Drug interaction; Panipenem; Valproic acid

Indexed keywords

BETAMIPRON; PANIPENEM; VALPROIC ACID;

ARTICLE; CASE REPORT; CHILD; DOSE TIME EFFECT RELATION; DRUG DISPOSITION; DRUG MECHANISM; DRUG METABOLISM; ENZYME INDUCTION; FEMALE; HUMAN; PRIORITY JOURNAL;

ADULT; ANTICONVULSANTS; BETA-ALANINE; CHILD, PRESCHOOL; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; MALE; THIENAMYCINS; VALPROIC ACID;

EID: 0031875927     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199808000-00008     Document Type: Article

References (12)

1. Levy RH, Moreland TA, Morselli PL, Guyot M, Brachet-Liermain A, Loiseau P. Carbamazepine/valproic acid interaction in man and rhesus monkey. Epilepsia 1984;25:338-45.
2. Mihaly GW, Vajda FJ, Miles JL, Louis WJ. Single and chronic dose pharmacokinetic studies of sodium valproate in epileptic patients. Eur Pharmacol 1979;15:23-9.
3. Sackellares JC, Sato S, Dreifuss FE, Penry JK. Reduction of steady state valproate levels by other antiepileptic drugs. Epilepsia 1981; 22:437-41.
4. Bowdle TA, Levy RH, Cutler RE. Effects of carbamazepine on valproic acid kinetics in normal subjects. Clin Pharmacol Ther 1979;26:629-34.
5. Mattson RH, Cramer JA, Williamson PD, Novelly RA. Valproic acid in epilepsy: clinical and pharmacological effects. Ann Neurol 1978;3:20-5.
6. Nakashima M, Uematsu T, Kanamura M, et al. Phase I study of panipenem/betamipron I: single dose study. Chemotherapy (Jpn) 1991;39(S-3):242-64.
7. Nakashima M, Uematsu T, Kanamura M, et al. Phase I study of panipenem/betamipron II: multiple dose study. Chemotherapy (Jpn) 1991;39(S-3):265-88.
8. Naganuma H, Tokiwa H, Hirouchi Y, et al. Nephroprotective effect and its mechanism of betamipron, I: relationships of renal transport. Chemotherapy (Jpn) 1991;39(S-3):166-77.
9. Takahagi H, Matsushita Y, Hirota T, et al. Metabolic studies on panipenem/betamipron: distribution, metabolism and excretion of panipenem/betamipron in rats and dogs. Chemotherapy (Jpn) 1991;39(S-3):206-26.
10. Hemphill DG, Mayer B, Breutzman D, et al. An Evaluation of Valproic Acid Method for the DuPont aca R Discrete Clinical Analyzer. Wilmington: DuPont Company; 1983.
11. Cramer JA, Mattson RH, Bennett DM, Swick CT. Variable free and total valproic acid concentrations in sole- and multi-drug therapy. Ther Drug Monit 1986;8:411-5.
12. Pollack GM, McHugh WB, Gengo FM, Ermer JC, Shen DD. Accumulation and washout kinetics of valproic acid and its active metabolites. J Clin Pharmacol 1986;26:668-76.